PDCD1 and neoplasm: In both the Y1.7LI melanoma model and MC38 model, NeoAg vaccines combined with either anti-CTLA-4 or anti-PD-1 leads to equal or even better anti-tumor immune responses than even combination anti-CTLA-4 and anti-PD-1.